ヒトパピローマウイルス予防ワクチン:グローバル医薬品市場予測及び分析(~2022)...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 21
3.2 Symptoms 23
4 Vaccination Recommendations and Coverage Rates 25
4.1 Vaccination Recommendations Overview 25
4.2 US 27
4.2.1 Vaccination Recommendations and Policies 27
4.2.2 Vaccination Coverage 27
4.2.3 Clinical Practice 29
4.3 France 30
4.3.1 Vaccination Recommendations and Policies 30
4.3.2 Vaccination Coverage 31
4.3.3 Clinical Practice 32
4.4 Germany 33
4.4.1 Vaccination Recommendations and Policies 33
4.4.2 Vaccination Coverage 34
4.4.3 Clinical Practice 35
4.5 Italy 36
4.5.1 Vaccination Recommendations and Policies 36
4.5.2 Vaccination Coverage 37
4.5.3 Clinical Practice 39
4.6 Spain 40
4.6.1 Vaccination Recommendations and Policies 40
4.6.2 Vaccination Coverage 41
4.6.3 Clinical Practice 43
4.7 UK 43
4.7.1 Vaccination Recommendations and Policies 43
4.7.2 Vaccination Coverage 44
4.7.3 Clinical Practice 45
4.8 Japan 46
4.8.1 Vaccination Recommendations and Policies 46
4.8.2 Vaccination Coverage 47
4.8.3 Clinical Practice 48
4.9 Australia 49
4.9.1 Vaccination Recommendations and Policies 49
4.9.2 Vaccination Coverage 49
4.9.3 Clinical Practice 51
4.10 Canada 52
4.10.1 Vaccination Recommendations and Policies 52
4.10.2 Vaccination Coverage 53
4.10.3 Clinical Practice 54
5 Competitive Assessment 56
5.1 Overview 56
5.2 Strategic Competitor Assessment 56
5.3 Product Profiles 58
5.3.1 Gardasil 58
5.3.2 Cervarix 64
6 Unmet Need and Opportunity 70
6.1 Overview 70
6.2 Protection against Multiple HPV Types 71
6.2.1 Unmet Need 71
6.2.2 Gap Analysis 72
6.2.3 Opportunity 73
6.3 Vaccine Coverage Rates 73
6.3.1 Unmet Need 73
6.3.2 Gap Analysis 74
6.3.3 Opportunity 74
6.4 Perception of Vaccine Safety 75
6.4.1 Unmet Need 75
6.4.2 Gap Analysis 76
6.4.3 Opportunity 76
6.5 Awareness of HPV Vaccination 77
6.5.1 Unmet Need 77
6.5.2 Gap Analysis 77
6.5.3 Opportunity 78
6.6 Affordability of HPV Vaccines 78
6.6.1 Unmet Need 78
6.6.2 Gap Analysis 79
6.6.3 Opportunity 79
6.7 Coverage of HPV Types Prevalent in Certain Populations 80
6.7.1 Unmet Need 80
6.7.2 Gap Analysis 81
6.7.3 Opportunity 81
6.8 Vaccine Compliance Rates 82
6.8.1 Unmet Need 82
6.8.2 Gap Analysis 82
6.8.3 Opportunity 83
6.9 Lifelong Protection from HPV Infection Not Established 83
6.9.1 Unmet Need 83
6.9.2 Gap Analysis 84
6.9.3 Opportunity 84
6.10 Ongoing Need for Cervical Cancer Screening 85
6.10.1 Unmet Need 85
6.10.2 Gap Analysis 85
6.10.3 Opportunity 86
7 Pipeline Assessment 87
7.1 Overview 87
7.2 Clinical Trial Mapping 88
7.2.1 Clinical Trials by Country 88
7.2.2 Clinical Trials by Phase and Trial Status 89
7.3 Promising Vaccines in Clinical Development 90
7.3.1 V503 92
7.3.2 Xiamen Innovax (Bivalent Vaccine) 98
7.4 Innovative HPV Vaccines in Early Development 101
7.4.1 Low-Cost HPV Vaccines 101
7.4.2 Universal HPV Vaccines 102
8 Current and Future Players 103
8.1 Overview 103
8.2 Trends in Corporate Strategy 105
8.3 Company Profiles 106
8.3.1 Merck 106
8.3.2 GSK 109
9 Market Outlook 112
9.1 Global Markets 112
9.1.1 Forecast 112
9.1.2 Drivers and Barriers – Global Issues 114
9.2 US 119
9.2.1 Forecast 119
9.2.2 Key Events 121
9.2.3 Drivers and Barriers 121
9.3 France 124
9.3.1 Forecast 124
9.3.2 Key Events 126
9.3.3 Drivers and Barriers 126
9.4 Germany 128
9.4.1 Forecast 128
9.4.2 Key Events 130
9.4.3 Drivers and Barriers 130
9.5 Italy 132
9.5.1 Forecast 132
9.5.2 Key Events 134
9.5.3 Drivers and Barriers 135
9.6 Spain 137
9.6.1 Forecast 137
9.6.2 Key Events 138
9.6.3 Drivers and Barriers 139
9.7 UK 141
9.7.1 Forecast 141
9.7.2 Key Events 142
9.7.3 Drivers and Barriers 143
9.8 Japan 145
9.8.1 Forecast 145
9.8.2 Key Events 146
9.8.3 Drivers and Barriers 147
9.9 Australia 149
9.9.1 Forecast 149
9.9.2 Key Events 151
9.9.3 Drivers and Barriers 151
9.10 Canada 153
9.10.1 Forecast 153
9.10.2 Key Events 154
9.10.3 Drivers and Barriers 155
10 Appendix 158
10.1 Bibliography 158
10.2 Abbreviations 174
10.3 Methodology 176
10.4 Forecasting Methodology 176
10.4.1 Vaccine Coverage 177
10.4.2 Vaccine Approval versus Routine Schedule Inclusion 177
10.4.3 Vaccines Included 178
10.4.4 Vaccine Launch Dates and Patent Expiry Dates 178
10.4.5 General Pricing Assumptions 178
10.4.6 Individual Drug Assumptions 179
10.4.7 Pricing of Pipeline Agents 181
10.5 Physicians and Specialists Included in this Study 182
10.6 About the Author(s) 185
10.6.1 Author(s) 185
10.6.2 Therapy Area Director 185
10.6.3 Global Head of Healthcare 186
10.7 About GlobalData 187
10.8 Disclaimer 187


【レポート販売概要】

■ タイトル:ヒトパピローマウイルス予防ワクチン:グローバル医薬品市場予測及び分析(~2022)
■ 英文:PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022
■ 発行日:2014年3月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC84PIDR
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。